Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
When traveling, your smart transmitter and sensor are safe to go through airport security without removing them. You may inform security that you have an implanted medical device.
Your smart transmitter will automatically sync to your smartphone’s current time and date when time zones are changed. You should allow for automatic syncing or manually change the time zone (not the time) if needed.
The Eversense® E3 CGM System is safe for use on U.S. commercial airlines. The Eversense® E3 Smart Transmitter is a Medical Portable Electronic Device (M-PED) with emission levels that meet FAA mandates for use in all modes while in flight. (Reference FAA Advisory, Circular #21-16G, dated 6.22.2011.) To use, turn your mobile device’s Bluetooth® feature on after you have put your mobile device in airplane mode. For flights outside the US, follow local security regulations for use of medical devices in flight.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses changes in the sensor’s glucose sensitivity. This sensitivity varies by individual, and from day to day. The need for 1 or 2 calibrations/day is determined by the system based on this continuous assessment, and there is no specific action a user can take to change the frequency of calibrations. However, providing the system with an accurate blood glucose value is important. Always calibrate the system using only a fingerstick blood sample. DO NOT calibrate at times when glucose may be rapidly changing (e.g., after meals, after dosing insulin). DO NOT use an alternative site (such as forearm or palm) blood glucose reading to calibrate the system.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses changes in the sensor’s glucose sensitivity. This sensitivity varies by individual, and from day to day. The need for 1 or 2 calibrations/day is determined by the system based on this continuous assessment, and there is no specific action a user can take to change the frequency of calibrations.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses the sensor’s glucose sensitivity and based on this information, the system determines whether 1 or 2 calibrations/day are needed after day 21. This ensures the best possible system accuracy is maintained.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060